Grufity logo
Grufity logo
SVRA

SVRA - Savara Inc Stock Price, Fair Value and News

$5.30-0.03 (-0.56%)
Market Closed as of 16 Jun 2026, 04:00 pm ET

12/100

SVRA

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

12/100

SVRA

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

SVRA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

SVRA Price Action

Last 7 days

5.1%

Last 30 days

5.8%

Last 90 days

3.3%

Trailing 12 Months

140.7%

SVRA RSI Chart

SVRA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

SVRA Valuation

Market Cap

1.1B

Price/Earnings (Trailing)

-8.39

Price/Sales (Trailing)

1.4K

EV/EBITDA

-14.22

Price/Free Cashflow

-10.16

SVRA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

SVRA Fundamentals

SVRA Revenue

Revenue (TTM)

751.0K

SVRA Earnings

Earnings (TTM)

-129.5M

Earnings Growth (Yr)

-39.96%

Earnings Growth (Qtr)

-15.66%

SVRA Profitability

EBT Margin

-10236.35%

Return on Equity

-73.55%

Return on Assets

-58.42%

Free Cashflow Yield

-9.84%

SVRA Investor Care

Shares Dilution (1Y)

18.66%

Diluted EPS (TTM)

-0.56

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2020--795.0K751.0K
2017597.5K---
2016140.5K227.0K313.5K400.0K
2015---54.0K
2010---489.0K
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Savara Inc

SVRA
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Austin, Texas.
 CEO
 WEBSITEsavarapharma.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES28

Savara Inc Frequently Asked Questions

SVRA is the stock ticker symbol of Savara Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Mon Jun 15 2026, market cap of Savara Inc is 1.09 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Mon Jun 15 2026, SVRA's PE ratio (Price to Earnings) is -8.44 and Price to Sales (PS) ratio is 1.42 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SVRA PE ratio will change depending on the future growth rate expectations of investors.